The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.
 
Kelly Sharon Chien
No Relationships to Disclose
 
Juan Jose Rodriguez-Sevilla
No Relationships to Disclose
 
Yesid Alvarado Valero
Honoraria - Astellas Pharma
Consulting or Advisory Role - MEI Pharma
Research Funding - Astex Pharmaceuticals (Inst); BerGenBio (Inst); Daiichi Sankyo/Lilly (Inst); FibroGen (Inst); Jazz Pharmaceuticals (Inst); Sun Pharma (Inst)
 
Guillermo Montalban Bravo
Research Funding - IFM Therapeutics (Inst); Takeda
 
Danielle Hammond
No Relationships to Disclose
 
Mahesh Swaminathan
No Relationships to Disclose
 
Alexandre Bazinet
No Relationships to Disclose
 
Jacqueline Kimberley
No Relationships to Disclose
 
Kristy Bodden
No Relationships to Disclose
 
Heather Schneider
No Relationships to Disclose
 
Xiao Qin Dong
No Relationships to Disclose
 
Sherry Pierce
No Relationships to Disclose
 
Xuelin Huang
No Relationships to Disclose
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Pfizer; Takeda
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Astellas Pharma; AstraZeneca/MedImmune; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; Jazz Pharmaceuticals (Inst); KAHR Medical; Novartis; Pfizer; Precision Biosciences; Shenzhen Target Rx; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis